Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Atavistik Bio, Inc
Eli Lilly and Company
Stemline Therapeutics, Inc.
AstraZeneca
Eli Lilly and Company
Eli Lilly and Company
AstraZeneca
Hoffmann-La Roche
Novartis
Hoffmann-La Roche
Myriad Genetic Laboratories, Inc.
Syndax Pharmaceuticals
Seagen Inc.
Sinocelltech Ltd.
Concure Oncology-Breast Microseed Inc.
Medifocus, Inc.
BBB-Therapeutics B.V.
Medco Health Solutions, Inc.